35 results on '"Long, Jieran"'
Search Results
2. Construction of an endoplasmic reticulum stress-related signature in lung adenocarcinoma by comprehensive bioinformatics analysis
3. Real-world data on the first-line immune checkpoint inhibitors or in combination with chemotherapy in older patients (aged ≥ 75 years) with advanced non-small cell lung cancer
4. Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC
5. Diagnosis and Treatment Characteristics of Lung Cancer Patients with Venous Thromboembolism
6. The overall survival benefit in Chinese ALK+ NSCLC patients received targeted therapies
7. A phase II study of bevacizumab in non-squamous, non-small-cell lung cancer patients with malignant pleural effusion
8. Molecular analysis of cell-free DNA identifies distinct molecular features in patients with chemosensitive and chemorefractory small cell lung cancer
9. Second‐line treatment options in advanced thymic carcinoma after failure of platinum‐based chemotherapy: A multicenter retrospective study
10. Second‐line treatment options in advanced thymic carcinoma after failure of platinum‐based chemotherapy: A multicenter retrospective study.
11. Comparison of endostatin combined with PT-DC versus bevacizumab combined with PT-DC in the first-line treatment of advanced lung adenocarcinoma: a retrospective propensity score- matched cohort study
12. Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC
13. sj-docx-1-tct-10.1177_15330338211039676 - Supplemental material for Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study
14. sj-docx-2-tct-10.1177_15330338211039676 - Supplemental material for Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study
15. sj-docx-4-tct-10.1177_15330338211039676 - Supplemental material for Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study
16. sj-pdf-3-tct-10.1177_15330338211039676 - Supplemental material for Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study
17. Losartan Supports Liver Regrowth via Distinct Boost of Portal Vein Pressure in Rodents with 90 % Portal Branch Ligation
18. Prognostic factor analysis of patients with small cell lung cancer: Real‐world data from 988 patients
19. Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From China
20. Identification of serum biomarkers to predict pemetrexed/platinum chemotherapy efficacy for advanced lung adenocarcinoma patients by data-independent acquisition (DIA) mass spectrometry analysis with parallel reaction monitoring (PRM) verification
21. Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study
22. A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer
23. Salvage treatment with anlotinib for advanced non‐small cell lung cancer
24. A phase I study to evaluate safety, tolerability, pharmacokinetics and antineoplastic activity of BPI-7711 in patients with EGFR/T790M mutation advanced or recurrent NSCLC.
25. Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma
26. Efficacy, safety and predictive indicators of apatinib after multilines treatment in advanced nonsquamous nonsmall cell lung cancer: Apatinib treatment in nonsquamous NSCLC
27. Efficacy and safety of endostar in the treatment of advanced lung squamous cell carcinoma.
28. Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma.
29. Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancer
30. Clinical characteristics associated with metastatic NSCLC harboring ALK rearrangements in Chinese patients.
31. Clinical characteristics associated with non-small-cell lung cancer harboring ALK rearrangements in Chinese patients
32. The overall survival benefit in Chinese ALK + NSCLC patients received targeted therapies.
33. [Timing of Brain Radiation Therapy Impacts Outcomes in Patients with Non-small Cell Lung Cancer Who Develop Brain Metastases].
34. [Effects of Local Radiation Combined with Chemotherapy in the treatment of Patients with Extensive-stage Small Cell Lung Cancer].
35. [Multivariate analysis of prognostic factors in the eldly patients with small cell lung cancer: a study of 160 patients].
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.